Skip to main content

Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales

Biogen Inc reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.